| Autor: |
Li X; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China., Sheng XN, Chi ZH, Cui CL, Si L, Mao LL, Tang BX, Lian B, Wang X, Yan XQ, Li SM, Bai X, Zhou L, Kong Y, Dai J, Guo J |
| Jazyk: |
čínština |
| Zdroj: |
Zhonghua yi xue za zhi [Zhonghua Yi Xue Za Zhi] 2018 Aug 28; Vol. 98 (32), pp. 2574-2578. |
| DOI: |
10.3760/cma.j.issn.0376-2491.2018.32.008 |
| Abstrakt: |
Objective: To observe the impact of first-line chemotherapy on renal function in patients with unresectable/metastatic upper tract urothelial carcinoma(UTUC). Methods: A total of 222 (130 males and 92 females) unresectable/metastatic upper tract urothelial carcinoma patients were included in the study between January 2005 and May 2017, with age of 29 to 87 (62.4±10.1) years old. The serum creatinine level and estimated glomerular filtration rate (eGFR) were compared before and after first-line chemotherapy. And predictive factors for decreased renal function were analyzed in logistic regression model. Results: After the first-line chemotherapy, the average serum creatinine level increased, with a median changing value of 1.5 μmol/L. Howerver, the eGFR improved, with a median changing value of 0.5 ml·min -1 · (1.73 m 2 ) -1, but the differences were not statistically significant (all P >0.05). In 149 patients who were treated with cisplatin-based chemotherapy, the average serum creatinine level increased by 1.31 μmol/L and eGFR improved by 0.14 ml·min -1 ·(1.73 m 2 ) -1, but the differences were not statistically significant ( P >0.05). In multivariate logistic regression model, age more than and equal to 60 years old ( OR =0.88, P =0.745) and cisplatin-based chemotherapy ( OR =0.95, P =0.893) did not increase the risk of renal dysfunction after first-line chemotherapy. If the time interval between surgery and first-line chemotherapy was more than 1 year, the risk of renal dysfunction due to chemotherapy decreased ( OR =0.54, P =0.196). Eastern Cooperative Oncology Group Performance Status (ECOG PS) Scale≥1 ( OR =1.81, P =0.131), anemia before treatment ( OR =1.14, P =0.764), the cycles of first-line chemotherapy ( OR =1.41, P =0.398) may lead to increase the risk of renal dysfunction, but the differences were not statistically significant. However in the patients who accepted nephrectomy, the risk of renal dysfunction after chemotherapy increased, but the difference was still not statistically significant ( OR =3.06, P =0.089). Conclusions: First-line chemotherapy, especially the cisplatin-based regimen, had no significant impact on renal function in the patients with UTUC. Nephrectomy maybe a predictive risk factor for decreased renal function after chemotherapy. Adequate assessment of renal function before treatment, hydration and close monitoring during chemotherapy can effectively protect renal function of the patients. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
